Preliminary Scientific Program

Print
DAY 1
15:15-15:30
Welcome Address
15:30-17:00
Session 1: Where do things Stand?
 
Ongoing and planned Clinical trials amongst the Cooperative Groups
17:00-17:30
Coffee Break
17:30-19:00
Session 2: Cytotoxics
Have we hit the wall? Is it likely that major advances will occur using cytotoxic chemotherapy?
 
How can the evaluation of cytotoxics be addressed in AML Subtypes?
19:00
Leukemia Club "Meet & Greet”

DAY 2
09:00-10:30
Session 3: The "known” Targets - FLT3, c-Kit, NPM1
The promises and the limitations of targeting FLT3
 
The promises and limitations of targeting c-kit
 
  
Can NPM1 be targeted? A critical appraisal of the ATRA trials
10:30-11:00
Coffee Break
11:00-13:00
Session 4: New Molecular Characterization 
 
Will there be many more new "discoveries”?
 
Implications of stem cell heterogeneity
 
Can mirs be targeted? Should we care?
 
Practical Problems related to Minimal Residual Disease Detection
13:00-14:00
Lunch
14:00-16:00
Session 5: Myelodysplasia
 
Has there been real progress in the treatment of MDS? A critical appraisal:
 
Does epigenetics really play a major role in MDS and is this really the mechanism of therapeutic effect?
 
What have we learned from the molecular characterization of MDS?
 
Should high grade MDS and AML patients be treated on the same trials?
16:00-16:30
Coffee Break
16:30-18:30
Session 6: Practical Impediments
 
Pharma perspective – The financial impediments to developing drugs for slivers of the molecular pie
 
Novel Trial designs for evaluating molecularly targeted treatments in AML subtypes
 
Can trials be done targeting minimal residual disease?
 
Panel Discussion
18:30
Leukemia Club "Meet & Greet”

DAY 3
08:30-11:00
Session 7: Stem Cell Transplant / Immunotherapy
What are the limits of SCT in AML?
 
AML therapy with immunoconjugates – a critical appraisal
 
The promise of Bispecific Antibodies?
11:00-11:30
Coffee Break
11:30-13:00
Session 8: Wrap-up session
Can international trials in small patient groups be coordinated?
 
How to involve pharma in this effort:
 
Final comments - Future prospects: